Golafshani Maryam, Buchman Daniel Z, Husain M Ishrat
MD Program, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Npj Ment Health Res. 2024 Jul 2;3(1):34. doi: 10.1038/s44184-024-00065-y.
Given the renewed interest in the use of psychedelics for the treatment of mental and substance use disorders in recent decades, there has also been renewed discussion and debate about whether it is necessary or beneficial for those who study and deliver psychedelic-assisted psychotherapy (PAP) to have had personal experience of using psychedelics. This paper provides a brief history of this debate and brings a disability-rights perspective to the discussion, given increasing efforts to dismantle ableism in medical training, practice, and research. Many psychiatric conditions and psychotropic medications, including ones as commonly prescribed as antidepressants, may preclude one from being able to safely and/or effectively use psychedelics. As such, we argue explicitly mandating or even implying the necessity of experiential training for psychedelic researchers and clinicians can perpetuate ableism in medicine by excluding those who cannot safely use psychedelics because of their personal medical histories. As PAP research and practice rapidly grow, we must ensure the field grows with disability inclusion amongst researchers and clinicians.
鉴于近几十年来人们对使用迷幻剂治疗精神和物质使用障碍重新产生了兴趣，关于研究和提供迷幻剂辅助心理治疗（PAP）的人员是否有使用迷幻剂的个人经历是否必要或有益，也重新展开了讨论和辩论。本文简要介绍了这场辩论的历史，并鉴于在医学培训、实践和研究中消除能力主义的努力不断增加，从残疾权利的角度参与讨论。许多精神疾病和精神药物，包括像抗抑郁药这样常用的药物，可能会使人无法安全和/或有效地使用迷幻剂。因此，我们认为，明确要求甚至暗示迷幻剂研究人员和临床医生进行体验式培训，可能会因为排除那些由于个人病史而无法安全使用迷幻剂的人，从而使医学中的能力主义长期存在。随着PAP研究和实践的迅速发展，我们必须确保该领域在研究人员和临床医生中纳入残疾人群体的情况下不断发展。
